Arca
Skip to content

Bronchopulmonary dysplasia

Drug research and approvals for bronchopulmonary dysplasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 47 studies of bronchopulmonary dysplasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 1 approved and 18 open orphan designations naming it.

  • Recruiting worldwide: 47
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 47 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Dec 6, 2019Helping underdeveloped lungs with cells (hulc): mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia - phase 1…ALLOGENEIC UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLSOTTAWA HOSPITAL RESEARCH INSTITUTEOngoing
May 16, 2019Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasiaSILDENAFILUNIVERSITY OF NORTH CAROLINAClosed
Nov 1, 2018Multi-centre randomized controlled trial of surfactant plus budesonide to improve survival free of bronchopulmonary dysplasia in extremely preterm infantsBUDESONIDEMURDOCH CHILDREN'S RESEARCH INSTITUTEClosed
Aug 1, 2018Pharmacokinetics and pharmacodynamics of budesonide with intratracheal surfactant (bits) administration in preterm infants < 29 weeks gestational ageBUDESONIDE/ BLES (BOVINE LIPID EXTRACT SURFACTANT)UNIVERSITY OF MANITOBAPending
Jun 21, 2017Evaluation of safety and thrombolytic effect of ascending doses of ds9231(ts23) in subjects with intermediate-risk (sub-massive) acute pulmonary embolism (pe)DS9231Daiichi SankyoPending
Jul 5, 2013The evaluation of the effectiveness of inhaled budesonide for non-ventilated infants at high risk of bronchopulmonary dysplasia: the i-bud pilot studyBUDESONIDESUNNYBROOK RESEARCH INSTITUTEPending

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 19
Jan 18, 1996RespigamFor the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary…MedImmune & Massachussetts Public Health Biologics Labs.Approved
Oct 25, 2022Human allogeneic umbilical cord mesenchymal stromal…Prevention of bronchopulmonary dysplasiaExo Biologics SADesignated
Aug 5, 2022Allogeneic umbilical cord-derived mesenchymal stem cell drugPrevention of Bronchopulmonary DysplasiaMeribank Biotech Co. Ltd.Designated
Jun 6, 2022azithromycinPrevention of bronchopulmonary dysplasia in neonates.Iorek Pharma LimitedDesignated
Jul 7, 2021mecasermin rinfabatePrevention of bronchopulmonary dysplasiaOHB Neonatology LtdDesignated
Feb 8, 2021Mesenchymal Stem Cell-derived Extracellular VesiclesPrevention of Bronchopulmonary Dysplasia in neonatesStella Kourembanas, M.D.Designated
Jan 18, 2021N-((2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(4-nit…Prevention of bronchopulmonary dysplasiaAyuVis Research, Inc.Designated
Nov 1, 2017recombinant fragment human surfactant protein-DPrevention of bronchopulmonary dysplasiaTrimunocor Ltd.Designated
Aug 8, 2016Retinol palmitatePrevention of bronchopulmonary dysplasia.Orphanix GmbHDesignated
Jul 14, 2015vitamin A palmitatePrevention of bronchopulmonary dysplasia.Advent Therapeutics, Inc.Designated
Jun 23, 2014recombinant human surfactant protein DPrevention of bronchopulmonary dysplasiaAirway Therapeutics LLCDesignated
Nov 26, 2013human umbilical cord blood-derived mesenchymal stem cellsPrevention of bronchopulmonary dysplasiaMEDIPOST America, Inc.Designated
Mar 26, 2010Water-miscible vitamin A palmitatePrevention of bronchopulmonary dysplasia.Fox Pharma, Inc.Designated
May 23, 2006LucinactantPrevention of bronchopulmonary dysplasia in premature infantsLee’s Pharmaceutical (HK) LimitedDesignated
Oct 21, 2005LucinactantTreatment of bronchopulmonary dysplasia in premature infants.Lee’s Pharmaceutical (HK) LimitedDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.